新型驱动基因融合阳性非小细胞肺癌脑转移的研究进展北大核心

肺癌是我国最常见且死亡率最高的恶性肿瘤之一,随着表皮生长因子受体(EGFR)、间变性淋巴瘤激酶(ALK)及活性氧1(ROS1)等驱动基因及其相应分子靶向药物的出现,晚期非小细胞肺癌的治疗和预后发生了革命性变化。此外,一些少见新型驱动基因融合,包括神经调节蛋白1(NRG1)、神经营养酪氨酸受体激酶(NTRK)和转染重排因子(RET),正逐渐发展成为全身性治疗选择。然而,这些罕见新型融合驱动基因在NSCLC脑转移中的作用机制,以及优化控制和预防脑转移的意义人们所知甚少。因此,本文就近几年罕见驱动基因融合在NSCLC脑转移中的研究进行综述。

Research progress of novel fusion drivers positive non-small cell lung cancer with brain metastasis

Lung cancer is the most common cancer,with the highest mortality in China.With the emergence of EGFR,ALK,ROS1 and their corresponding targeted agents,the treatment and prognosis of advanced non-small cell lung cancer have undergone revolutionary changes.In addition,there are a number of emerging fusion drivers,including neurotrophin kinase (NTRK),rearrangement during transfection (RET),and neuregulin 1 (NRG1),are gradually evolving systemic treatment options.Little is known,however,on the molecular mechanisms of brain metastases,and their significance in optimizing the control and prevention of brain metastasis in non-small cell lung cancer with rare fusion drivers.Here,we provide a review in the progress of current rare fusion driver genes and their corresponding targeted drugs in non-small cell lung cancer with brain metastasis.